dostarlimab
gsk
['dostarlimab']
 possibly there's something here above preclinical charactization says "dostarlimab had little to no binding to complement protein c1q or fc , receptors that elicit cdc or adcc, respectively,19 and hence is unlikely to result in the depletion of antitumor effector t cells" 